Lactococci and lactobacilli as mucosal delivery vectors for therapeutic proteins and DNA vaccines

LG Bermúdez-Humarán, P Kharrat, JM Chatel… - Microbial cell …, 2011 - Springer
Abstract Food-grade Lactic Acid Bacteria (LAB) have been safely consumed for centuries by
humans in fermented foods. Thus, they are good candidates to develop novel oral vectors …

Development of a Stress-Inducible Controlled Expression (SICE) system in Lactococcus lactis for the production and delivery of therapeutic molecules at mucosal …

B Benbouziane, P Ribelles, C Aubry, R Martin… - Journal of …, 2013 - Elsevier
In recent years, recombinant lactic acid bacteria (LAB) have been successfully used as safe
mucosal delivery vectors. Herein, we report on the development of a Stress-Inducible …

Advances in human papilloma virus vaccines: a patent review

HJ Cho, YK Oh, YB Kim - Expert opinion on therapeutic patents, 2011 - Taylor & Francis
Introduction: Human papilloma virus (HPV) infection is the main factor associated with the
development of cervical cancer. The currently available HPV vaccines, Gardasil and …

Oral immunization of mice with engineered Lactobacillus gasseri NM713 strain expressing Streptococcus pyogenes M6 antigen

NM Mansour, SA Abdelaziz - Microbiology and immunology, 2016 - Wiley Online Library
The aim of this in vivo study was to evaluate the effects of a recombinant probiotic strain,
Lactobacillus gasseri NM713, which expresses the conserved region of streptococcal M6 …

[HTML][HTML] Oral administration of Lactococcus lactis expressing synthetic genes of myelin antigens in decreasing experimental autoimmune encephalomyelitis in rats

K Kasarello, B Kwiatkowska-Patzer… - … Medical Journal of …, 2015 - ncbi.nlm.nih.gov
Background Multiple sclerosis is a human autoimmunological disease that causes
neurodegeneration. One of the potential ways to stop its development is induction of oral …

Anti-viral treatment and cancer control

WL Shih, CT Fang, PJ Chen - Viruses and Human Cancer: From Basic …, 2014 - Springer
Hepatitis B virus (HBV), hepatitis C virus (HCV), human papillomavirus (HPV), and Epstein–
Barr virus (EBV) contribute to about 10–15% global burden of human cancers. Conventional …

HPV vaccines: state of the art

G D'Andrilli, A Bovicelli… - Journal of cellular …, 2010 - Wiley Online Library
Cervical cancer is one of the most common types of cancer in women worldwide and is
frequent in relatively young women. In the last decades, its incidence has decreased …

Preclinical pharmacokinetics and biodistribution of human papillomavirus DNA vaccine delivered in human endogenous retrovirus envelope-coated baculovirus …

HJ Cho, S Lee, S Im, MG Kim, J Lee, HJ Lee… - Pharmaceutical …, 2012 - Springer
Purpose Test pharmacokinetics and biodistribution of a human papillomavirus (HPV) 16L1
DNA vaccine delivered in human endogenous retrovirus envelope protein (HERV) …

Adeno-associated virus-mediated local delivery of LIGHT suppresses tumorigenesis in a murine cervical cancer model

M Maitituoheti, Y Li, W Wang, W Wang… - Journal of …, 2011 - journals.lww.com
LIGHT is a tumor necrosis factor superfamily ligand that is considered as a promising
candidate for cancer therapy. It has a potent antitumor activity through establishing lymphoid …

Human papillomavirus immunogen that provides protective tumor immunity and induces tumor regression

JP Marquez, R Rivera, KH Kang, MB Gardner… - Viral …, 2012 - liebertpub.com
Human papillomavirus (HPV) is associated with premalignant lesions such as high-grade
cervical intraepithelial neoplasia (CIN-III) with potential progression to cervical carcinoma …